目的 探討重組牛堿性成纖維細(xì)胞生長因子眼用凝膠聯(lián)合地夸磷索鈉滴眼液治療白內(nèi)障術(shù)后干眼癥的臨床療效。方法 選取2022年7月-2023年7月滄州市眼科醫(yī)院收治的60例白內(nèi)障術(shù)后干眼癥患者,隨機(jī)分為對照組(30例)和治療組(30例)。對照組患者眼部滴注地夸磷索鈉滴眼液,1~2滴/次,4次/d。在對照組基礎(chǔ)上,治療組涂抹重組牛堿性成纖維細(xì)胞生長因子眼用凝膠,2次/d。兩組患者治療7 d。觀察兩組患者臨床療效,比較治療前后兩組患者緩解癥狀時(shí)間,眼表熒光素染色(FL)和眼表疾病指數(shù)(OSDI)評(píng)分,及血清白細(xì)胞介素-1β(IL-1β)、丙二醇(MDA)、腫瘤壞死因子-α(TNF-α)和超氧化物歧化酶(SOD)水平。結(jié)果 治療后,治療組臨床總有效率為96.67%,明顯高于對照組(73.33%,P<0.05)。治療后,治療組癥狀好轉(zhuǎn)時(shí)間均明顯早于對照組(P<0.05)。治療后,兩組患者FL、OSDI評(píng)分比治療前明顯下降(P<0.05),且治療組患者下降更明顯(P<0.05)。治療后,兩組患者血清IL-1β、TNF-α和MDA水平明顯降低,而SOD水平明顯升高(P<0.05),且治療組患者血清因子水平明顯好于對照組(P<0.05)。結(jié)論 重組牛堿性成纖維細(xì)胞生長因子眼用凝膠與地夸磷索鈉滴眼液協(xié)同治療,可有效恢復(fù)臨床癥狀,改善眼部炎性反應(yīng)狀態(tài)。

Objective To explore the clinical curative effect of Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel combined with Diquafosol Sodium Eye Drops in treatment of dry eye after cataract surgery. Methods Patients (60 cases) with dry eye after cataract surgery in Cangzhou Eye Hospital from July 2022 to July 2023 were randomly divided into control (30 cases) and treatment (30 cases) group. Patients in the control group were administered with Diquafosol Sodium Eye Drops, 1-2 drops/time, four times daily. Patients in the treatment group were administered with Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel on the basis of the control group, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, the scores FL and OSDI, and the levels of serum IL-1β, TNF-α, MDA and SOD in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 96.67%, which was significantly higher than that of the control group (73.33%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the scores of FL and OSDI in two groups were significantly lower than those before treatment (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the serum levels of IL-1β, TNF-α and MDA in two groups decreased significantly, while the level of SOD was significantly increased (P < 0.05), and the level of serum factors in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion The combination of Recombinant Bovine Basic Fibroblast Growth Factor Eye-Gel and Diquafosol Sodium Eye Drops can effectively restore clinical symptoms and improve the state of ocular inflammatory reaction.

R988.1

河北省衛(wèi)生健康委醫(yī)學(xué)科學(xué)研究課題計(jì)劃項(xiàng)目（20200343）